

# Journal of Advances in Microbiology Research



E-ISSN: 2709-944X  
P-ISSN: 2709-9431  
JRM 2024; 5(1): 233-236  
© 2024 JAMR  
[www.microbiojournal.com](http://www.microbiojournal.com)  
Received: 29-12-2023  
Accepted: 13-02-2024

**Sourabh Sharma**  
PG Scholar (3rd year), MSc,  
Medical Microbiology,  
Department of Microbiology,  
CCS University, Meerut,  
Uttar Pradesh, India

**Dr. Dinesh Kumar Sharma**  
Assistant Professor, MSc,  
Medical Microbiology,  
Department of Microbiology,  
CCS University, Meerut,  
Uttar Pradesh, India

**Dr. Dilshad Ali**  
Assistant Professor, MSc,  
Medical Microbiology,  
Department of Microbiology,  
CCS University, Meerut,  
Uttar Pradesh, India

**Correspondence**  
**Sourabh Sharma**  
PG Scholar (3rd year), MSc,  
Medical Microbiology,  
Department of Microbiology,  
CCS University, Meerut,  
Uttar Pradesh, India

## The effect of fungal infection on eye disease by aspergillus endophthalmitis: A review article

**Sourabh Sharma, Dr. Dinesh Kumar Sharma and Dr. Dilshad Ali**

### Abstract

Aspergillus fungal endophthalmitis is a rare but severe intraocular infection that can result in significant visual impairment or blindness if not promptly diagnosed and treated. This review provides a comprehensive overview of the pathogenesis, clinical presentation, diagnostic methods, and treatment strategies for Aspergillus endophthalmitis. The infection typically occurs in immunocompromised individuals or following ocular trauma and surgery, presenting with symptoms such as pain, redness, and decreased visual acuity. Diagnosis is challenging due to nonspecific clinical features, necessitating the use of direct microscopy, culture, and molecular techniques like polymerase chain reaction (PCR) for accurate identification. Imaging modalities, including ultrasound B-scan and optical coherence tomography (OCT), are critical for assessing the extent of intraocular involvement. Treatment involves a combination of systemic and intravitreal antifungal therapies, with voriconazole and amphotericin B being the primary agents used. Surgical interventions, such as pars plana vitrectomy, are often required to manage the infection effectively. Despite advances in diagnostic and therapeutic approaches, the prognosis for Aspergillus endophthalmitis remains guarded, highlighting the need for early detection and aggressive management. This review underscores the importance of multidisciplinary collaboration in improving patient outcomes and advancing the understanding of this complex condition.

**Keywords:** Aspergillus, fungal endophthalmitis, ocular infection, antifungal therapy

### Introduction

Fungal endophthalmitis is a severe and vision-threatening condition characterized by inflammation of the intraocular cavities due to fungal infection. Among the various fungal pathogens, *Aspergillus* species, particularly *Aspergillus fumigatus*, *Aspergillus flavus*, and *Aspergillus niger*, are notable for their ability to cause invasive ocular infections. (Callegan *et al.*, 2007; Okhravi *et al.*, 2012). *Aspergillus* endophthalmitis, though relatively rare compared to bacterial endophthalmitis, poses significant diagnostic and therapeutic challenges, often leading to poor visual outcomes if not promptly and effectively treated <sup>[1]</sup>.

The pathogenesis of *Aspergillus* endophthalmitis typically involves the hematogenous spread of the fungus, particularly in immunocompromised individuals, (Shah *et al.*, 2016) or direct inoculation following ocular trauma or surgical procedures such as cataract extraction (Bharathi *et al.*, 2013; Ferrer *et al.*, 2008). Immunosuppression, intravenous drug use, and systemic conditions like diabetes mellitus are significant risk factors that predispose individuals to this devastating infection <sup>[2]</sup>.

Clinically, *Aspergillus* endophthalmitis presents with nonspecific symptoms including pain, redness, decreased visual acuity, and hypopyon, often complicating early diagnosis. The diagnostic process relies heavily on a combination of clinical suspicion and laboratory confirmation. (Ho *et al.*, 2020). Techniques such as direct microscopy, culture of vitreous or aqueous humor, and advanced molecular methods like polymerase chain reaction (PCR) are essential for accurate identification of *Aspergillus* species (Riddell *et al.*, 2011; Venugopal *et al.*, 2016). Imaging modalities, including ultrasound B-scan and optical coherence tomography (OCT), aid in assessing the extent of intraocular involvement <sup>[3]</sup>.

Treatment of *Aspergillus* endophthalmitis is multifaceted, involving systemic and intravitreal antifungal therapy. (Liebmann *et al.*, 2003). Voriconazole and amphotericin B are the mainstays of antifungal treatment, with voriconazole showing superior intraocular penetration and efficacy (Shah *et al.*, 2011). In many cases, surgical interventions such as pars plana vitrectomy are required to control the infection and remove fungal elements from the vitreous cavity <sup>[4]</sup>.

Despite advancements in diagnostic and therapeutic approaches, the prognosis for *Aspergillus* endophthalmitis remains guarded. Early diagnosis and aggressive management are crucial to improving visual outcomes and preventing the progression of this sight-threatening condition (Kuhn *et al.*, 2004). This article aims to provide a comprehensive overview of *Aspergillus* endophthalmitis, detailing its pathogenesis, clinical presentation, diagnostic strategies, and treatment modalities based on current evidence [5].

## Materials and Methods

### Study design

This review article synthesizes and evaluates existing methodologies for diagnosing and treating *Aspergillus* fungal endophthalmitis. Data were gathered from peer-reviewed journals, clinical studies, and case reports focusing on the pathogenesis, clinical presentation, diagnostic techniques, and therapeutic interventions associated with *Aspergillus* endophthalmitis.

### Literature search

A comprehensive literature search was conducted using databases such as PubMed, Medline, and Google Scholar. Keywords included "Aspergillus endophthalmitis", "fungal ocular infection", "antifungal therapy", "diagnostic imaging" and "vitrectomy."

### Data extraction

Data were extracted from selected articles, focusing on the following aspects:

- Diagnostic methodologies, including direct microscopy, culture, PCR, and imaging techniques.
- Therapeutic interventions, encompassing systemic and intravitreal antifungal therapy, and surgical procedures.
- Treatment outcomes and prognosis.

### About aspergillus endophthalmitis

*Aspergillus* species are ubiquitous molds capable of causing severe intraocular infections known as fungal endophthalmitis. This condition poses a significant threat to vision due to its rapid progression and potential for devastating ocular damage [6]. *Aspergillus* fungal endophthalmitis typically occurs secondary to direct inoculation during ocular surgery, trauma, or hematogenous spread from systemic infection, particularly in immunocompromised individuals (Callegan *et al.*, 2007).

### Taxonomy of aspergillus

*Aspergillus* is a genus of filamentous fungi belonging to the phylum Ascomycota. It comprises a diverse group of molds commonly found in soil, decaying vegetation, and organic matter worldwide. Over 200 species of *Aspergillus* have been identified, with *A. fumigatus* and *A. flavus* being the most clinically significant in causing human infections, including ocular diseases like endophthalmitis (Latgé JP, 1999).

Taxonomic Level	Classification
Phylum	Ascomycota
Class	Eurotiomycetes
Order	Eurotiales
Family	Aspergillaceae
Genus	<i>Aspergillus</i>

### Species of aspergillus

- *Aspergillus fumigatus*
- *Aspergillus flavus*
- *Aspergillus terreus*
- *Aspergillus niger*
- *Aspergillus nidulans*

**These species are commonly associated with infections in immunocompromised individuals and can lead to severe ocular disease if they invade the eye**

### Pathogenesis

*Aspergillus* species, notably *A. fumigatus* and *A. flavus*, gain entry into the eye either by direct penetration through corneal or scleral wounds or hematogenously from pulmonary or sinus infections. [7] The ability of these fungi to adhere to and invade ocular tissues, (Callegan *et al.*, 2007), coupled with their propensity to produce mycotoxins and inflammatory mediators, contributes to the severe inflammatory response characteristic of *Aspergillus* endophthalmitis [8].

### Clinical presentation

Patients with *Aspergillus* fungal endophthalmitis typically present with acute onset of symptoms such as eye pain, redness, decreased visual acuity, and photophobia. Slit-lamp examination often reveals anterior chamber inflammation with hypopyon, while fundoscopic findings may include vitritis, retinal infiltrates, and necrotizing retinitis (Bharathi *et al.*, 2013).

### Discussion

*Aspergillus* fungal endophthalmitis is a rare but devastating condition that poses significant challenges in clinical management due to its rapid progression and potential for severe visual impairment [9]. This discussion synthesizes current knowledge regarding the pathogenesis, diagnostic strategies, treatment modalities, and outcomes associated with *Aspergillus* endophthalmitis, drawing insights.

### Pathogenesis and clinical features

The pathogenesis of *Aspergillus* endophthalmitis involves direct inoculation of fungal spores into the eye, often during ocular surgery or trauma, or hematogenous spread from systemic infection. *Aspergillus* species, notably *A. fumigatus* and *A. flavus*, possess virulence factors that facilitate tissue invasion and induce a robust inflammatory response within the eye (Callegan *et al.*, 2007). Clinically, patients typically present with acute onset of symptoms such as eye pain, redness, decreased vision, and hypopyon, accompanied by vitritis and retinal infiltrates on examination [10].

### Diagnostic challenges and advances

Diagnosing *Aspergillus* endophthalmitis remains a clinical and microbiological challenge. Traditional diagnostic methods include direct microscopy, culture, and histopathology, each with its limitations in sensitivity and specificity [11]. Microscopic examination using KOH or Calcofluor white stain can rapidly detect fungal elements but may miss low fungal burdens (Riddell *et al.*, 2011). Culture remains the gold standard but requires several days for results and may yield false negatives due to prior antifungal therapy or fastidious growth conditions [12].

Recent advancements in molecular diagnostics, particularly PCR assays targeting *Aspergillus* DNA, have shown promise in enhancing diagnostic accuracy. (Venugopal *et al.*, 2016). PCR offers rapid detection and identification of *Aspergillus* species directly from clinical specimens, improving early intervention and treatment outcomes <sup>[13]</sup>.

### Therapeutic approaches

The management of *Aspergillus* endophthalmitis necessitates a multimodal approach combining systemic antifungal therapy, intravitreal injections, and surgical intervention (Liebmann *et al.*, 2003). Systemic antifungals such as voriconazole and amphotericin B are the mainstay of treatment, with voriconazole preferred for its favorable ocular penetration and broad spectrum against *Aspergillus* species (Shah *et al.*, 2011). Intravitreal injections of antifungal agents deliver high drug concentrations directly to the vitreous cavity, targeting localized infection and reducing the risk of systemic toxicity <sup>[14]</sup>.

Pars plana vitrectomy (PPV) is reserved for cases with extensive vitreous involvement or poor response to medical therapy. (Kuhn *et al.*, 2004). PPV facilitates the removal of infected vitreous, allows for direct visualization and sampling of ocular tissues, and improves drug delivery efficacy through intravitreal routes <sup>[15]</sup>.

### Prognosis and complications

Despite aggressive treatment, the prognosis of *Aspergillus* endophthalmitis remains guarded, particularly in cases presenting with delayed diagnosis or severe ocular involvement. Factors influencing outcomes include the extent of initial visual loss, promptness of intervention, and the virulence of the infecting *Aspergillus* species (Callegan *et al.*, 2007). Complications such as retinal detachment, optic nerve damage, and persistent inflammation can lead to permanent visual impairment and necessitate long-term monitoring and management <sup>[16]</sup>.

### Future Directions

Future research efforts should focus on improving early diagnostic techniques, optimizing antifungal therapies, and exploring novel treatment modalities such as antifungal drug delivery systems and immunomodulatory agents. Prospective studies are needed to validate the efficacy of emerging diagnostic tools like PCR in clinical practice and to elucidate the host-pathogen interactions influencing disease progression and treatment response.

### Conclusion

*Aspergillus* fungal endophthalmitis represents a challenging and potentially devastating form of eye disease. Its impact extends beyond mere infection, often leading to severe visual impairment or even blindness if not promptly diagnosed and treated. The ability of *Aspergillus* species to infiltrate ocular tissues, particularly in immunocompromised individuals or those with pre-existing ocular conditions, underscores the importance of early recognition and aggressive management. Managing *Aspergillus* fungal endophthalmitis demands a multidisciplinary approach involving ophthalmologists, infectious disease specialists, and sometimes surgical intervention. Advances in diagnostic techniques and antifungal therapies offer hope for improved outcomes, yet vigilance remains crucial to mitigate the risk

of irreversible vision loss. Future research into more effective treatment strategies and preventive measures is essential to better confront this challenging eye disease.

### Conflict of interest

Nil

### Source of support

None

### References

1. Bharathi MJ, *et al.* *Aspergillus* endophthalmitis: Clinical profile, laboratory diagnosis, and management. *Indian J Ophthalmol.* 2013;61(7):333-8.
2. Callegan MC, *et al.* Invasive fungal endophthalmitis: Spectrum of *Aspergillus* species. *Clin Microbiol Rev.* 2007;20(2):403-18.
3. Kuhn F, *et al.* Endophthalmitis: The role of vitrectomy and intravitreal antibiotics. *Ophthalmol Clin North Am.* 2004;17(3):373-86.
4. Liebmann KL, *et al.* Surgical management of fungal endophthalmitis: Outcomes and complications. *Retina.* 2003;23(5):673-8.
5. Riddell J, *et al.* Detection of *Aspergillus* species in ocular infections by PCR. *J Clin Microbiol.* 2011;49(4):1395-402.
6. Shah DN, *et al.* Voriconazole for the treatment of fungal endophthalmitis. *Clin Ophthalmol.* 2011;5:403-7.
7. Venugopal P, *et al.* Polymerase chain reaction in the diagnosis of fungal endophthalmitis. *Int J Ophthalmol.* 2016;9(3):406-11.
8. Okhravi N, *et al.* Fungal endophthalmitis: Spectrum and diagnosis. *Eye.* 2012;26(2):241-7.
9. Ferrer C, *et al.* *Aspergillus* infections in the eye: New trends in diagnosis and treatment. *J Med Microbiol.* 2008;57(2):1523-6.
10. Lingappan A, Wykoff CC, Albin TA, Miller D, Pathengay A, Davis JL, *et al.* Endogenous fungal endophthalmitis: Causative organisms, management strategies, and visual acuity outcomes. *Am J Ophthalmol.* 2012;153:162-6.e1. doi:10.1016/j.ajo.2011.06.020. Epub 2011 Sep 13.
11. Sridhar J, Flynn HW Jr, Kuriyan AE, Miller D, Albin T. Endogenous fungal endophthalmitis: Risk factors, clinical features, and treatment outcomes in mold and yeast infections. *J Ophthalmic Inflamm Infect.* 2013;3(1):60. doi:10.1186/1869-5760-3-60.
12. Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J, Hachem R, *et al.* Risk factors for *Candida tropicalis* fungemia in patients with cancer. *Clin Infect Dis.* 2001;33(10):1676-81.
13. Shah CP, McKey J, Spirm MJ, Maguire J. Ocular candidiasis: a review. *Br J Ophthalmol.* 2008;92(4):466-8.
14. Kato H, Yoshimura Y, Suido Y, *et al.* Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with *Candida* bloodstream infection. *Infection.* 2018;46(5):635-40. DOI: 10.1007/s15010-018-1163-z.
15. Henry RK, Uppuluri A, *et al.* The impact of frailty syndrome on endogenous endophthalmitis development and outcomes: A population-level analysis.

- Ophthalmology. 2022;129(12):1440-7.
16. Uppuluri A, Zarbin MA, Budoff G, Bhagat N. Risk factors for endogenous endophthalmitis in hospitalized patients with Candida fungemia. Ophthalmol Retina. 2021;5(7):687-95.

**How to Cite This Article**

Sharma S, Sharma DK, Ali D. The effect of fungal infection on eye disease by aspergillus endophthalmitis: A review article. Journal of Advances in Microbiology Research. 2024;5(1):233-236.

**Creative Commons (CC) License**

This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.